Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Regen BioPharma (RGBPP) over the last 12 years, with Q4 2025 value amounting to -$22.7 million.

  • Regen BioPharma's Retained Earnings fell 825.02% to -$22.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$22.7 million, marking a year-over-year decrease of 825.02%. This contributed to the annual value of -$21.7 million for FY2025, which is 624.23% down from last year.
  • Regen BioPharma's Retained Earnings amounted to -$22.7 million in Q4 2025, which was down 825.02% from -$21.7 million recorded in Q3 2025.
  • Over the past 5 years, Regen BioPharma's Retained Earnings peaked at -$14.5 million during Q1 2021, and registered a low of -$87.8 million during Q1 2022.
  • For the 5-year period, Regen BioPharma's Retained Earnings averaged around -$23.8 million, with its median value being -$20.8 million (2021).
  • Per our database at Business Quant, Regen BioPharma's Retained Earnings tumbled by 50645.8% in 2022 and then soared by 7798.66% in 2023.
  • Over the past 5 years, Regen BioPharma's Retained Earnings (Quarter) stood at -$20.7 million in 2021, then grew by 6.93% to -$19.3 million in 2022, then fell by 4.3% to -$20.1 million in 2023, then decreased by 4.15% to -$20.9 million in 2024, then decreased by 8.25% to -$22.7 million in 2025.
  • Its Retained Earnings stands at -$22.7 million for Q4 2025, versus -$21.7 million for Q3 2025 and -$21.1 million for Q2 2025.